Phase 2 Non-Alcoholic Fatty Liver Disease (NCT04881760) This Phase 2A clinical trial was a sub-study of the Phase 2 clinical trial in obesity mentioned earlier, done for the purpose of measuring changes in liver fat and other associated biomarkers within people suffering from metabolic dysfunctionassociated steatotic liver disease (MASLD)
Tirzepatide: Zepbound and Mounjaro Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it works through two pathways instead of one
The entry of Novo Nordisk's GLP-1 receptor agonist Ozempic (semaglutide) into the Korean reimbursement market marks a significant shift in Korea's type 2 diabetes treatment landscape
ensuring a stable effect over 24 hours without causing any discomfort
However, many individuals are now exploring natural GLP-1 supplements as a way to support similar physiological pathways through nutrition and supplementation
A few months later, in January 1987 the group reported that the porcine peptide stimulated a small increase of insulin secretion from an isolated perfused pig pancreas and that they had observed a similar effect with a synthetic replica of the natural hormone
